Dr. Rizzieri focuses on developing new therapies for patients with leukemia or lymphoma. He is a member of the Combined International Bone Marrow Transplant Registry Lymphoma Writing Committee and the ALLIANCE (formerly CALGB) Leukemia Core Committee and NCI Leukemia Working Groups. Dr. Rizzieri serves as chair or co-chair of multiple ALLIANCE lymphoma/ leukemia trials, the most recent being the last two national studies for Burkitt’s lymphoma, as well as the current leukemia in under 60-year-olds study. He has led their team’s novel approaches for the care of patients using monoclonal antibodies with non-myeloablative allogeneic therapy to optimize a less toxic regimen for transplant of patients with hematologic malignancies using haplo-identical, as well as matched, donors. This work is currently being extended with post-transplant graft manipulation studies focused on manipulating Natural Killer cell activity. Dr. Rizzieri has led the development of anti-stromal therapy in lymphoma using new antibodies targeting the stromal protein, tenascin, for which a patent is pending, and first in-human studies targeting acute myelogenous leukemia by linking diphtheria to an antibody to the IL-3 receptor.
Duke University Medical Center: Ambulatory Surgery Center, 2400 Pratt St, Durham, NC 27705, USA
Get the latest thought leadership on Acute Myeloid Leukemia delivered straight to your inbox.
Subscribe to the weekly "HealthTree Community for Acute Myeloid Leukemia Newsletter" for Acute Myeloid Leukemia news, life
Acute Myeloid Leukemia stories, Acute Myeloid Leukemia clinical trials, Acute Myeloid Leukemia 101 articles and events with Acute Myeloid Leukemia
Thanks to our HealthTree Community for Acute Myeloid Leukemia Sponsors:
HealthTree Foundation is a qualified 501(c)(3) tax-exempt organization.